Guggenheim Maintains Buy on Enliven Therapeutics, Lowers Price Target to $78
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Michael Schmitz maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lowers the price target from $80 to $78.
Guggenheim analyst Michael Schmitz maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lowers the price target from $80 to $78.